DeLeve L D
Department of Pharmacology, Hospital for Sick Children, Toronto, Ont., Canada.
Mutat Res. 1996 Nov 4;371(1-2):105-8. doi: 10.1016/s0165-1218(96)90099-3.
Dinitrochlorobenzene (DNCB) is clinically efficacious in the therapy of alopecia areata, but its use was limited when it was found to be mutagenic in the Ames test. However, there has been renewed interest in the immunomodulatory benefits of topically applied dinitrochlorobenzene in patients with human immunodeficiency virus and systemic lupus erythematosus. The current study examines the genotoxicity of dinitrochlorobenzene in human skin fibroblasts using sister chromatid exchange. Dinitrochlorobenzene caused a significant increase in sister chromatid exchange at concentrations ranging from 2.5 to 10 microM. Thus, dinitrochlorobenzene is genotoxic in human skin fibroblasts at concentrations well below those used clinically. The potential for long-term toxicity from dinitrochlorobenzene will have to be weighed against the severity and prognosis of the diseases for which it is used.
二硝基氯苯（DNCB）在斑秃治疗中具有临床疗效，但在艾姆斯试验中发现其具有致突变性后，其应用受到限制。然而，人们对局部应用二硝基氯苯对人类免疫缺陷病毒和系统性红斑狼疮患者的免疫调节益处重新产生了兴趣。当前的研究使用姐妹染色单体交换检测二硝基氯苯对人皮肤成纤维细胞的遗传毒性。二硝基氯苯在2.5至10微摩尔的浓度范围内可导致姐妹染色单体交换显著增加。因此，二硝基氯苯在远低于临床使用浓度时对人皮肤成纤维细胞具有遗传毒性。必须权衡二硝基氯苯长期毒性的可能性与其所治疗疾病的严重程度和预后。
